QLS2309 / Qilu Pharma - LARVOL DELTA

QLS2309, a trifunctional NKp46/CD16a-NK cell engager targeting CD70 enhances efficacy against acute myeloid leukemia via mitigating the refraction to therapeutic antibody-dependent cytotoxicity (AACR 2026) - P1 | "In vivo studies demonstrated dose-dependent tumor growth inhibition with QLS2309, showing superior efficacy compared to cusatuzumab (an ADCC-enhanced monoclonal antibody). These data support QLS2309 as a promising novel therapy for AML. A Phase 1 dose-escalation study in CD70+ relapsed/refractory hematologic malignancies is currently ongoing (NCT07173595)."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD70 • FCGR3A • TNFA

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1 | N=186 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Oncology

A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1 | N=186 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial • Hematological Malignancies • Oncology